Brought to you by 
Axovant licenses worldwide rights to Benitec's BB301 and five other CNS gene therapy programs
05 Jan 2021
Executive Summary
Axovant Sciences Ltd. licensed exclusive worldwide rights to Benitec Biopharma Ltd.'s preclinical oculopharyngeal muscular dystrophy (OPMD) candidate BB301, which Axovant has renamed AXO-AAV-OPMD. The two will also collaborate on five neurology programs incorporating Benitec's DNA-directed RNA interference (ddRNAi) platform.
Deal Industry
- Pharmaceuticals
-
Pharmaceuticals
-
Drug Delivery
- Macromolecule
-
Drug Delivery
-
Biotechnology
- Antisense, Oligonucleotides
- Gene Therapy, Cell Therapy
- Large Molecule
Deal Status
- Final
Deal Type
-
Alliance
- Includes Royalty or Profit Split Information
- Intra-Biotech Deal
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Axovant licenses worldwide rights to Benitec's BB301 and five other CNS gene therapy programs
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice